Navigating Treatment Decisions

This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient’s immune system attack the cancer cells. Immunotherapy treatments have been available for decades and have generated renewed interest for treating metastatic RCC patients. Two types of immunotherapy may be used for treating patients with metastatic RCC: interleukin-2 (IL-2), which is given intravenously, and interferon (IFN), which is injected under the skin.1 Several systemic therapies available for RCC patients are called“anti-angiogenic” drugs. During angiogenesis, tumors create blood vessels inside the tumor. These blood vessels supply nutrients and help the tumor to grow. Anti-angiogenic drugs can help to reduce the growth of tumor blood vessels, which in turn can make the tumor stop growing or shrink. Anti-angiogenic drugs that are used for treating RCC include sunitinib, pazopanib, sorafenib, and axitinib.1 All of these drugs come in a ...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Authors: Rodenburg RJ, Eskens F Abstract Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with disease progression during or after cytokine therapy. Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient se...
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Conclusions: Mechanical ventilation leads to down-regulation of R-spondin1. R-spondin1 may enhance the interaction of leucine-rich repeat containing G-protein coupled receptor 5 and apoptosis-stimulating protein of p53 2, thus inactivating p53-mediated proapoptotic pathway in cyclic stretched mouse lung vascular endothelial cells. R-spondin1 may have clinical benefit in alleviating mechanical ventilator-induced lung injury.
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Laboratory Investigation Source Type: research
Conclusions: A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials.
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Clinical Investigations Source Type: research
Source: Journal of Biomedical Nanotechnology - Category: Nanotechnology Authors: Tags: Articles Source Type: research
Source: Journal of Biomedical Nanotechnology - Category: Nanotechnology Authors: Tags: Articles Source Type: research
Source: Journal of Biomedical Nanotechnology - Category: Nanotechnology Authors: Tags: Articles Source Type: research
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient&rs...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Anemia | Avastin | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Clinical Trials | Hospitals | Hypertension | Immunotherapy | Kidney Cancer | Men | Nutrition | Oral Cancer | Pain | Radiation Therapy | Renal Cell Carcinoma | Skin | Study | Urology & Nephrology | Vaccines | Websites